Automated CT Scans Give Doctors a New Window Into a Rare Cystic Lung Disease

For patients living with pulmonary Langerhans cell histiocytosis, a rare disease that scars and hollows the lungs with countless cysts, the journey from diagnosis to treatment has long depended on something surprisingly subjective: a radiologist’s eye. Doctors examine computed tomography scans, visually grade the extent of the damage, and estimate how badly the lungs are functioning. Now a team of French researchers has shown that a fully automated, numbers-driven approach to reading those same scans can match expert judgment with remarkable precision, opening the door to a more objective way of tracking one of medicine’s most elusive lung diseases.

The study, led by Amira Benattia of Université Paris Cité and the French National Reference Centre for Histiocytoses at Hôpital Saint-Louis in Paris, was published in BMC Medical Imaging as a prospective pilot investigation. Eighteen patients with cystic pulmonary Langerhans cell histiocytosis underwent paired inspiratory and expiratory CT scans alongside a battery of pulmonary function tests performed at the same visit. The researchers then ran the imaging data through three complementary quantitative analysis pipelines: conventional densitometry, parametric response mapping, and a vascular analysis tool known as CALIPER. The results, they report, demonstrate for the first time that these automated biomarkers are not only feasible in this rare disease but agree closely with expert visual scoring.

Pulmonary Langerhans cell histiocytosis is an uncommon interstitial lung disease, seen almost exclusively in smokers, in which abnormal immune cells accumulate in and around the small airways. Over time, the inflammation gives way to a distinctive pattern of nodules, cavities, and eventually thin-walled cysts scattered throughout the lungs. Because the disease is rare, large clinical trials are difficult to mount, and clinicians have lacked validated, objective tools to measure how much lung tissue is affected or how the damage progresses over time. Visual scoring systems exist, but they are inherently reader-dependent: two experienced radiologists looking at the same scan may grade the extent of disease differently, and the same reader may grade it differently on different days.

The Paris team attacked this problem with parametric response mapping, a technique originally developed for chronic obstructive pulmonary disease. The method works by co-registering inspiratory and expiratory CT scans of the same patient, voxel by voxel, and comparing lung density between the two breathing phases. Each tiny cube of lung tissue is then classified into one of three categories: normal density, persistent low-density areas that represent structurally destroyed tissue such as cysts and emphysema, and functional small airways disease, where air is trapped because the small bronchioles are narrowed or obstructed. In a disease like pulmonary Langerhans cell histiocytosis, where cystic destruction and small airway involvement coexist in the same lungs, this three-way classification promised something clinicians had never had: a way to separate the two processes quantitatively.

The findings were striking. Automated densitometry and parametric response mapping measurements of the cystic lesions correlated with expert visual scoring at correlation coefficients of at least 0.80 across the board, and the agreement between the automated and human assessments was excellent, with an intraclass correlation coefficient of 0.96 and a 95 percent confidence interval of 0.91 to 0.99. Just as importantly, the automated metrics tracked with physiology. The extent of persistent low-density tissue on CT correlated significantly with the diffusing capacity of the lungs for carbon monoxide, a standard pulmonary function measure that reflects how efficiently oxygen and carbon dioxide cross the delicate membrane between air and blood. In statistical terms, the numbers on the scan were telling the same story as the numbers on the breathing tests.

Perhaps the most intriguing result emerged when the researchers adjusted their analysis for smoking history, measured in pack-years. Because nearly all patients with this disease are smokers, and smoking itself causes emphysema and small airway damage, disentangling the effects of the histiocytosis from the effects of tobacco is a persistent challenge. In multivariate linear regression models adjusted for pack-years, the persistent low-density fraction measured by parametric response mapping remained significantly associated with all pulmonary function test parameters, independent of the functional small airways disease fraction. This suggests that the cystic destruction characteristic of the disease carries measurable functional consequences of its own, beyond whatever damage smoking has inflicted on the small airways.

The small airways story proved more complicated. The functional small airways disease values varied considerably among patients who had similar forced expiratory volume in one second percentages, a standard measure of airflow obstruction. The authors interpret this variability as evidence of genuine heterogeneity in small airway involvement across the patient population, rather than as a failure of the technique. In other words, two patients with the same overall airflow limitation may arrive there by different routes, one dominated by cystic destruction and another by widespread bronchiolar obstruction. If confirmed in larger cohorts, this kind of quantitative phenotyping could eventually help clinicians understand why some patients deteriorate rapidly while others remain stable for years, and could help stratify patients in future therapeutic trials.

The study also ventured beyond the airways and into the blood vessels. Using CALIPER, or Computer-Aided Lung Informatics for Pathology Evaluation and Rating, the team quantified pulmonary vascular volume, a surrogate measure of the blood vessel bed within the lungs. Vascular involvement is an increasingly recognized dimension of the disease, and the analysis revealed a significant inverse association between the regional extent of cystic destruction and pulmonary vascular volume, with a p-value of 0.002. Where the cysts were most extensive, the vascular tree was most depleted, a finding that fits with the understanding that the disease process destroys not only airspaces but also the capillary networks that supply them, potentially contributing to pulmonary hypertension, a feared complication of advanced disease.

None of this means automated imaging is ready to replace the radiologist tomorrow. The study was a pilot, involving eighteen patients at a single expert centre, and the authors are careful to frame their conclusions as proof of feasibility rather than validated clinical practice. The correlation and agreement statistics are encouraging, but the confidence intervals reflect a small sample, and the technique requires high-quality paired inspiratory-expiratory scans, careful co-registration, and standardized acquisition protocols that are not yet universal. The researchers themselves call for further evaluation of the biomarkers’ potential value for disease phenotyping and longitudinal assessment, the two applications where quantitative imaging could ultimately matter most.

Still, the significance of the work extends well beyond one rare disease. Quantitative CT biomarkers have transformed the study of common conditions like emphysema and idiopathic pulmonary fibrosis, enabling objective endpoints in drug trials and deeper understanding of disease subtypes. Rare diseases have largely been left out of that revolution, precisely because small patient populations make validation difficult. By demonstrating that parametric response mapping, densitometry, and vascular quantification can be applied successfully to pulmonary Langerhans cell histiocytosis, the Paris group has laid the methodological groundwork for the kind of rigorous, measurable, multi-centre research that rare disease patients have long been denied. For a condition where every patient counts, teaching machines to read the lungs with precision may prove to be more than a technical achievement; it may be the first step toward trials that can actually change outcomes.

Subject of Research: Automated quantitative CT imaging biomarkers for assessing pulmonary Langerhans cell histiocytosis

Article Title: Feasibility of automated quantitative CT imaging metrics in pulmonary Langerhans cell histiocytosis: a pilot study

Article References: Feasibility of automated quantitative CT imaging metrics in pulmonary Langerhans cell histiocytosis: a pilot study. (n.d.). https://doi.org/10.1186/s12880-026-02932-w

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02932-w

Keywords: pulmonary Langerhans cell histiocytosis, quantitative CT, parametric response mapping, densitometry, CALIPER, cystic lung disease, lung function, imaging biomarkers, pulmonary vascular volume, small airways disease, rare disease, radiology